Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Med
Main Authors: Darici, Salihanur, Alkhaldi, Hazem, Horne, Gillian, Jørgensen, Heather G., Marmiroli, Sandra, Huang, Xu
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563273/
https://ncbi.nlm.nih.gov/pubmed/32932888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092934
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki